High-throughput mouse model for optimizing antibody affinities

Patent metadata

Field	Value
Publication number	US-10034463-B2
Application number	US-201515112557-A
Country	US
Kind code	B2
Filing date	Jan 23, 2015
Priority date	Jan 24, 2014
Publication date	Jul 31, 2018
Grant date	Jul 31, 2018

Abstract

Described herein are compositions (e.g. cells and transgenic animals) and methods relating to engineered Ig loci that permit expression of particular antibodies or antibody segments while still permitting recombination and/or maturation process for antibody optimization.

First claim

We claim:

1. A cell comprising an engineered IgH locus
in which the 3′-most V H segment of the IgH locus comprises a cassette targeting sequence; and
the engineered IgH locus further comprises a non-functional IGCR1 sequence within the nucleic acid sequence separating the 3′ end of the 3′-most V H segment of the IgH locus and the 5′ end of a D H segment of the IgH locus.

2. The cell of claim 1 , wherein the cassette targeting sequence permits the replacement of the 3′-most V H segment.

3. The cell of claim 1 , wherein the cassette targeting sequence is selected from the group consisting of:
an I-SceI meganuclease site; a Cas9/CRISPR target sequence; a Talen target sequence or a recombinase-mediated cassette exchange system.

4. The cell of claim 1 , wherein the 3′-most V H segment of the IgH locus has been engineered to comprise a non-native V H segment sequence.

5. The cell of claim 4 , wherein the non-native V H segment is a human V H segment.

6. The cell of claim 4 , wherein the non-native V H segment is a human V H segment from a known antibody in need of improvement of affinity or specificity.

7. The cell of claim 1 , further comprising:
(a) a 3′ recombinase site being located 3′ of the one or more J H segments;
and a passenger cassette being located at the position of a deleted native 3′-most V H segment, the passenger cassette comprising, from 5′ to 3′:
a 5′ recombinase site
an inverted passenger VDJ exon and/or a cassette targeting sequence; and
a maturation-compatible V H segment;

wherein the recombinase sites are inverted with respect to each other; or
(b) a 3′ recombinase site being located 3′ of the one or more J H segments;
and a passenger cassette being located at the position of a deleted native 3′-most V H segment, the passenger cassette comprising, from 5′ to 3′:
a 5′ to 3′-oriented passenger VDJ exon and/or a cassette targeting sequence;
a 5′ recombinase site; and
a maturation-compatible V H segment;

wherein the recombinase sites are in the same orientation.

8. A genetically engineered mouse comprising the cell of claim 1 .

9. A chimeric genetically engineered mouse comprising two populations of cells,
a first population comprising cells which are V(D)J recombination-defective; and
a second population comprising cells of claim 1 .

10. A method of making an optimized antibody from a known antibody, the method comprising the steps of:
injecting a mouse blastocyst with a cell of claim 1 , wherein the cell is a mouse embryonic stem cell, and wherein the V H segment comprises the V H segment of the known antibody at the position of the native 3′ most V H segment;
implanting the mouse blastocyst into a female mouse under conditions suitable to allow maturation of the blastocyst into a genetically engineered mouse;
isolating
1) an optimized antibody comprising the non-native V H segment; or
2) a cell producing an optimized antibody comprising the non-native V H segment from the genetically engineered mouse.

11. A method of identifying a candidate antigen as an antigen that activates a B cell population comprising a V H segment of interest, the method comprising:
immunizing a mammal of claim 8 , engineered such that a majority of the mammal's peripheral B cells express the V H segment of interest, with the antigen;
measuring B cell activation in the mammal; and
identifying the candidate antigen as an activator of a B cell population comprising the V H segment of interest if the B cell activation in the mammal is increased relative to a reference level.

12. The cell of claim 1 , wherein the non-functional IGCR1 sequence comprises mutated CBE sequences; the CBE sequences of the IGCR1 sequence have been deleted; or the IGCR1 sequence has been deleted from the IgH locus.

13. The cell of claim 1 , wherein the cell is a murine cell.

14. The cell of claim 13 , wherein the cell is a murine stem cell or murine embryonic stem cell.

15. The cell of claim 1 , wherein the cell is a stem cell or embryonic stem cell.

16. The cell of claim 7 , wherein the recombinase site is a LoxP site and the cell further comprises a locus encoding cre recombinase.

17. The cell of claim 16 , wherein the locus encoding cre recombinase is under the control of a promoter which is not active in immature B cells and is active in peripheral B cells.

18. The cell of claim 17 , wherein the promoter is the CD21 promoter.

19. The cell of claim 1 , wherein the IgH locus further comprises at least one of the following:
one or more non-native D H segments;
one native D H segment;
one or more non-native J H segments, the
a human J H 2 J H segment;
one native J H segment;
a murine IgH locus sequence;
a human IgH locus sequence; and/or
a humanized IgH locus sequence.

20. The cell of claim 1 , wherein the J H locus has been replaced by human D and J H cassette or a cassette with an assembled human DJ H .

21. The cell of claim 1 , wherein the cell is heterozygous for the engineered IgH locus of claim 1 and the other IgH locus has been engineered to be inactive, wherein the cell will express an IgH chain only from the engineered IgH locus of claim 1 .

22. The cell of claim 1 , further comprising at least one of the following:
an IgL locus with human sequence;
a humanized IgL locus;
a human IgL locus;
an IgL locus with one V L segment;
an IgL locus with one J L segment;
a human rearranged V L J L at the IgL kappa or lambda locus;
a human rearranged V L J L at the murine IgL kappa or lambda locus; and
an IgL locus encoding IGκV1 or VRC01 IgL.

23. The cell of claim 1 , further comprising a mutation capable of activating, inactivating or modifying genes lead to increased GC antibody maturation responses.

Assignees

• Childrens Medical Center

Inventors

• Alt Frederick
• Cheng Hwei-Ling
• Tian Ming

Classifications

• C07K16/114

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• A01K2267/01

  Animal expressing industrially exogenous proteins · CPC title

• A01K2207/15

  Humanized animals · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C12N2800/30

  Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT · CPC title